NanoString Expands Leadership Team With the Hiring of Two Seasoned Executives

  NanoString Expands Leadership Team With the Hiring of Two Seasoned

    Added Experience in Quality, Regulatory and Legal Supports Diagnostics

Business Wire

SEATTLE -- February 28, 2013

NanoString Technologies, Inc., a privately held provider of life science tools
for translational research and molecular diagnostic products, today announced
the appointment of Gary S. Riordan as Vice President of Quality and Regulatory
Affairs and Kathy Surace-Smith as Vice President and General Counsel. Both
executives bring many years of experience in their respective fields, as well
as in the medical technology industry. Mr. Riordan and Ms. Surace-Smith are
expected to play key roles in advancing the company’s diagnostic business,
which recently launched its first commercial in vitro diagnostic product, the
Prosigna^™ Breast Cancer Prognostic Gene Signature Assay for the nCounter^®
diagnostic system in the European Union and Israel.

Gary Riordan has more than 20 years of experience working in the in vitro
diagnostics field. Most recently he served in senior leadership roles with
several privately-held diagnostic companies and as a consultant to the
industry. Previously, he was Vice President of Quality and Regulatory Affairs
and a member of the senior management team at Sequenom, Inc. and Director of
Regulatory Affairs at Ventana Medical Systems, Inc., which was acquired by
Roche Molecular Systems. Earlier in his career, Mr. Riordan was a biologist at
the Food and Drug Administration and served as a primary reviewer of premarket
approval and product license applications. He received his B.A. in Molecular
Biology from San Jose State University.

Kathy Surace-Smith joins NanoString after serving for eight years as Vice
President, General Counsel and Corporate Secretary of SonoSite, Inc., a
Nasdaq-listed medical device company specializing in hand held ultrasound
systems. At SonoSite, Ms. Surace-Smith managed diverse matters including
intellectual property, litigation, compliance, licensing, board governance and
reimbursement. Previously, she was Vice President and General Counsel at
Metawave Communications, a Nasdaq-listed telecommunications equipment
provider, where she was part of the management team that took the company
public. Earlier in her career, Ms. Surace-Smith was in private practice with
Gibson, Dunn & Crutcher. She received her A.B. from Princeton University and a
J.D. from Columbia University School of Law.

“With the addition of these two high-caliber individuals, our leadership team
has the key ingredients needed to successfully pursue our expansion into
molecular diagnostics,” said Brad Gray, President and Chief Executive Officer
of NanoString Technologies. “Kathy and Gary each bring a wealth of experiences
that will add significant value to our company now and in the future, and I am
very pleased to have them join our team.”

About NanoString Technologies, Inc.

NanoString Technologies is a privately held provider of life science tools for
translational research and developer of molecular diagnostic products. The
company’s nCounter^® Analysis System, which has been employed in basic and
translational research since it was first introduced in 2008 and cited in more
than 180 peer-reviewed publications, has also now been optimized as a
diagnostic platform. The system offers a cost-effective way to easily profile
the expression of hundreds of genes, miRNAs, or copy number variations,
simultaneously with high sensitivity and precision. The company’s technology
enables a wide variety of basic research and translational medicine
applications, including biomarker discovery and validation. The nCounter-based
Prosigna™ Breast Cancer Prognostic Gene Signature Assay is the first in vitro
diagnostic kit to be marketed through the company’s recently formed
diagnostics business.

The nCounter Analysis System is currently available for “Research Use Only” in
North America. For more information, please visit

The NanoString Technologies logo, NanoString, NanoString Technologies and
nCounter are registered trademarks, and Prosigna is a trademark, of NanoString
Technologies, Inc.


For NanoString Technologies
Maurissa Messier, 760-539-7417
Press spacebar to pause and continue. Press esc to stop.